We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
-1.61%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$21M
(+22%)
Cap. Flow
+$284M
Cap. Flow
% of AUM
244.1%
Top 10 Holdings %
Top 10 Hldgs %
42.12%
Holding
462
New
171
Increased
79
Reduced
68
Closed
122
Top Buys
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$4.59M |
| 2 |
Biogen
BIIB
|
+$3.56M |
| 3 |
Cal-Maine
CALM
|
+$2.79M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$2.48M |
| 5 |
Apple
AAPL
|
+$2.33M |
Top Sells
| 1 |
Baxter International
BAX
|
+$4.11M |
| 2 |
Gilead Sciences
GILD
|
+$2M |
| 3 |
IBM
IBM
|
+$1.48M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$930K |
| 5 |
Expedia Group
EXPE
|
+$914K |
Sector Composition
| 1 | Healthcare | 41.4% |
| 2 | Technology | 6.27% |
| 3 | Consumer Staples | 4.14% |
| 4 | Consumer Discretionary | 2.26% |
| 5 | Materials | 1.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
CALL
American Airlines Group
AAL
$9.91B
| $135K | 0.12% |
+55,000
| New | +$1.86M |
|
127
CALL
3M
MMM
$83.4B
| $130K | 0.11% |
+46,644
| New | +$6.58M |
|
128
CALL
PepsiCo
PEP
$187B
| $129K | 0.11% |
165,000
-58,100
| -26% | -$6M |
|
129
KLA
KLAC
$278B
| $126K | 0.11% |
+17,170
| New | +$123K |
|
|
130
PUT
Bristol-Myers Squibb
BMY
$124B
| $123K | 0.11% |
50,000
+30,100
| +151% | +$2.13M |
|
131
CALL
Yum! Brands
YUM
$40.8B
| $122K | 0.1% |
+38,253
| New | +$2.25M |
|
132
PUT
Salesforce
CRM
$140B
| $120K | 0.1% |
+12,500
| New | +$981K |
|
|
133
CALL
Biogen
BIIB
$30.4B
| $118K | 0.1% |
37,200
+5,000
| +16% | +$1.32M |
|
134
CALL
PTC Therapeutics
PTCT
$6.52B
| $116K | 0.1% |
90,400
-32,500
| -26% | -$238K |
|
135
CALL
Acadia Pharmaceuticals
ACAD
$4.38B
| $115K | 0.1% |
10,900
-103,800
| -90% | -$3.47M |
|
|
JUNO
136
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
| $115K | 0.1% |
+60,000
| New | +$2.49M |
|
137
CALL
Arrowhead Research
ARWR
$10.5B
| $114K | 0.1% |
85,800
+22,000
| +34% | +$126K |
|
138
CALL
Mondelez International
MDLZ
$78.3B
| $112K | 0.1% |
+76,000
| New | +$3.31M |
|
139
Qualcomm
QCOM
$181B
| $112K | 0.1% |
+2,100
| New | +$111K |
|
140
CALL
Church & Dwight Co
CHD
$23.2B
| $106K | 0.09% |
+35,600
| New | +$1.72M |
|
|
SPLK
141
PUT
DELISTED
Splunk Inc
SPLK
| $106K | 0.09% |
+18,300
| New | +$966K |
|
142
PUT
Five Below
FIVE
$11.2B
| $105K | 0.09% |
52,800
+3,200
| +6% | +$134K |
|
143
PUT
Intel
INTC
$478B
| $105K | 0.09% |
156,500
+126,100
| +415% | +$3.95M |
|
|
144
PUT
Yum! Brands
YUM
$40.8B
| $105K | 0.09% |
+38,253
| New | +$2.25M |
|
|
MJN
145
CALL
DELISTED
Mead Johnson Nutrition Company
MJN
| $105K | 0.09% |
16,500
| – | – |
|
|
TYC
146
PUT
DELISTED
TYCO INTL PLC COM SHS (IRL)
TYC
| $105K | 0.09% |
+41,924
| New | +$1.76M |
|
147
CALL
lululemon athletica
LULU
$13.2B
| $104K | 0.09% |
24,000
+4,000
| +20% | +$265K |
|
148
PUT
Bank OZK
OZK
$5.68B
| $104K | 0.09% |
+20,000
| New | +$788K |
|
149
CALL
Applied Materials
AMAT
$421B
| $102K | 0.09% |
47,000
+38,900
| +480% | +$858K |
|
|
AGN
150
CALL
DELISTED
Allergan plc
AGN
| $102K | 0.09% |
10,300
-13,000
| -56% | -$3M |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q2 2016 Portfolio in Review
As of Q2 2016, FT Options held 462 positions worth $116M, up 22% from $95.5M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
FT Options deployed $284M of net new capital in Q2 2016, opening 171 new positions and adding to 79 existing holdings. Its largest new stake was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the largest reduction was Gilead Sciences, an estimated $2M trimmed.
- FT Options's largest Q2 2016 buy was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
- FT Options added most to MEDIVATION, INC. in Q2 2016, an estimated $4.59M increase.
- FT Options's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $2M.
- FT Options fully exited Baxter International in Q2 2016, selling an estimated $4.11M.
- FT Options's ten largest holdings make up 42% of its $116M portfolio in Q2 2016.
- FT Options opened 171 new positions and closed 122 in Q2 2016.
- FT Options's portfolio value rose 22% quarter-over-quarter to $116M.
Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.